Monique Nicoll
Exelixis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Monique Nicoll.
Developmental Cell | 2002
Ross Francis; Garth McGrath; Jianhuan Zhang; David A. Ruddy; Mary Sym; Javier Apfeld; Monique Nicoll; Mark E. Maxwell; Bing Hai; Michael C. Ellis; Annette L. Parks; Wei Xu; Jinhe Li; Mark E. Gurney; Richard L. Myers; Carol S. Himes; Ronald Hiebsch; Cara Ruble; Jeffrey S. Nye; Daniel Tim Curtis
Presenilins are components of the gamma-secretase protein complex that mediates intramembranous cleavage of betaAPP and Notch proteins. A C. elegans genetic screen revealed two genes, aph-1 and pen-2, encoding multipass transmembrane proteins, that interact strongly with sel-12/presenilin and aph-2/nicastrin. Human aph-1 and pen-2 partially rescue the C. elegans mutant phenotypes, demonstrating conserved functions. The human genes must be provided together to rescue the mutant phenotypes, and the inclusion of presenilin-1 improves rescue, suggesting that they interact closely with each other and with presenilin. RNAi-mediated inactivation of aph-1, pen-2, or nicastrin in cultured Drosophila cells reduces gamma-secretase cleavage of betaAPP and Notch substrates and reduces the levels of processed presenilin. aph-1 and pen-2, like nicastrin, are required for the activity and accumulation of gamma-secretase.
Bioorganic & Medicinal Chemistry Letters | 2012
Joerg Bussenius; Charles M. Blazey; Naing Aay; Neel Kumar Anand; Arlyn Arcalas; Tae-Gon Baik; Owen Joseph Bowles; Chris A. Buhr; Simona Costanzo; Jeffrey K. Curtis; Steven Charles Defina; Larisa Dubenko; Timothy S. Heuer; Ping Huang; Christopher Jaeger; Anagha Abhijit Joshi; Abigail R. Kennedy; Angie I. Kim; Katherine Lara; Jae Lee; Jonathan Li; Julie Lougheed; Sunghoon Ma; Shiva Malek; Jean-Claire Limun Manalo; Jean‐Francois Martini; Garth McGrath; Monique Nicoll; John M. Nuss; Michael Pack
With structural guidance, tropane-derived HTS hits were modified to optimize for HSP90 inhibition and a desirable in vivo profile. Through an iterative SAR development process 12i (XL888) was discovered and shown to reduce HSP90 client protein content in PD studies. Furthermore, efficacy experiments performed in a NCI-N87 mouse xenograft model demonstrated tumor regression in some dosing regimens.
Genetics | 2005
Kyle A. Edgar; Marcia Belvin; Annette L. Parks; Kellie Whittaker; Matt B. Mahoney; Monique Nicoll; Christopher C. Park; Christopher Winter; Feng Chen; Kim Lickteig; Ferhad Ahmad; Hanife Esengil; Matthew V. Lorenzi; Amanda Norton; Brent A. Rupnow; Laleh Shayesteh; Mariano Tabios; Lynn Marie Young; Pamela Carroll; Casey Kopczynski; Gregory D. Plowman; Lori S. Friedman; Helen Francis-Lang
Archive | 2003
Helen Francis-Lang; Siobhan Roche; Daniel M. Joo; Monique Nicoll; Bing Hai; Haiguang Zhang; Kim Lickteig; Craig D. Amundsen; Yisheng Jin; Joanne I. Adamkewicz; Darren Mark Platt; R. Glenn R. Hammonds
Archive | 2003
Helen Francis-Lang; Monique Nicoll; Timothy S. Heuer
Archive | 2004
Helen Francis-Lang; Siobhan Roche; Timothy S. Heuer; Monique Nicoll
Cancer Research | 2009
Monique Nicoll
Archive | 2007
Kyle A. Edgar; Kimberly Carr Ferguson; Monique Nicoll; Christopher Winter
Archive | 2007
Kyle Andrew Edgar; Kimberly Carr Ferguson; Monique Nicoll; Christopher G. Winter
Archive | 2006
Joanne I. Adamkewicz; Craig D. Amundsen; Lynn Margaret Bjerke; George Ross Francis; Timothy S. Heuer; Kim Lickteig; Monique Nicoll